Compare Biogen Inc (BIIB) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Motorola Solutions Inc — how do they compare? Biogen Inc trades at $196.33 (market cap $28.34B), while Motorola Solutions Inc trades at $410.09 (market cap $68.67B). The key difference: Motorola Solutions Inc is far larger — about 2.4× Biogen Inc's market cap, and Motorola Solutions Inc pays a 1.17% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MSI | |
|---|---|---|
Market Cap | $28.34B | $68.67B |
Sector | Health | Technology |
52-Week High | $216.63 | $490.30 |
52-Week Low | $122.68 | $363.83 |
Enterprise Value | $30.62B | $77.38B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Motorola Solutions (MSI) trades at $418.06, down 1.14% today, with a neutral technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $11.68B and net income of $2.15B, supported by a 99.88% ROE. Recent developments include the $1.5B D-Fend acquisition and AI expansion for emergency response systems, positioning MSI for growth in public safety technology.
MSI presents a compelling investment case with analyst consensus price target of $512.33 (22.5% upside) and 71% buy ratings. Strong profitability and strategic AI investments are offset by high valuation multiples (P/E 33.71) and negative cash flow from significant acquisitions. Key risks include integration challenges from recent deals and competitive pressure in the public safety sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
